ICF - Institut Català de Finances
VC Fund
Barcelona, Spain
ICF - Institut Català de Finances is a VC fund in Barcelona focused on Medical and Health Care. ICF - Institut Català de Finances provides financial services.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries ICF - Institut Català de Finances invests in
Stages ICF - Institut Català de Finances invests in
Countries ICF - Institut Català de Finances invests in
Round sizes
Round size
- Seed
- $2.4M–$10M
- Debt Financing
- $1.7M–$12M
Investment Focus
Industry
- Medical 4 (22%)
- Health Care 4 (22%)
- Biotechnology 4 (22%)
- Pharmaceutical 4 (22%)
- Manufacturing 3 (17%)
Stage
- Debt Financing 12 (67%)
- Seed 3 (17%)
- Series C 1 (6%)
- Funding Round 1 (6%)
- Post-IPO Debt 1 (6%)
Country
- Spain 15 (83%)
- Germany 1 (6%)
- United Kingdom 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ALLOX is a biotechnology company developing an experimental and artificial intelligence platform for drug discovery. The company combines high-throughput genetics, experimental biology, computational biology, and machine learning to identify functional regions in proteins, including allosteric sites that regulate protein activity. Its proprietary platform uses systematic mutagenesis to measure how thousands of genetic mutations affect protein function, structure, and interactions. These experimental datasets provide the foundation for computational models that predict potential therapeutic targets and guide the design of small-molecule drugs. ALLOX focuses on discovering druggable sites in proteins that have historically been difficult to target, including protein-protein interactions and transcription factors. Its initial research programs focus on oncology, with potential applications across other disease areas. The company also develops its own drug discovery pipeline and collaborates with pharmaceutical and biotechnology partners on research programs. ALLOX originated as a spin-off from the Centre for Genomic Regulation and applies its platform to the discovery of new therapeutic approaches for diseases with limited treatment options. | $10.5M / Seed / Oct 29, 2026 | ||
| Grup Pons is an agricultural food company that produces estate-grown extra virgin olive oils under the Pons and Janiroc lines. The company manages a vertically integrated model that covers olive cultivation, milling, bottling, and global distribution. Grup Pons also operates Clos Pons, a winery that produces wines, cavas and vermouths that reflect its Mediterranean grape varieties and viticulture. Alongside oils and wines, the portfolio includes bittersweet wine vinegars, sherry vinegars, balsamic-style vinegars, saffron and pantry items. The business serves both professional kitchens and retail consumers, offering single-estate monovarietal oils, organic ranges and curated gift selections. Grup Pons sells its products through international distributors and its own online channels. | $1.3M / Debt Financing / Oct 22, 2026 | ||
| Open Cosmos is a space technology company that designs, builds, and operates satellites to simplify access to space. The company also delivers end-to-end telecommunications, Earth Observation (EO), navigation, and scientific missions. It designs, builds, launches and operates advanced satellites through its OpenOrbit offering, that enablesorganizations to access and share data via its mutualized OpenConstellation infrastructure and offers AI-powered data analysis from a growing range of satellite sources and analytic partners through its DataCosmos platform. | $346.4M / Series C / Sep 14, 2026 | ||
|
Delta Renovables
|
Delta Renovables specializes in the creation, promotion, operation, and maintenance of renewable energy projects. | $4.6M / Debt Financing / Aug 04, 2026 | |
| Ercros is a chemical manufacturing company that focuses on the basic products for the chemical and pharmaceutical industries. The company diversified in three areas of activity such as the Pharmacy Division, the Chlorine Derivatives Division, and the Intermediate Chemistry Division. It maintains a leading position in the main markets in which it ispresent and exports almost half of its sales to more than 128 countries, mainly in the EU.Ercros was founded in 1989 and is headquartered in Barcelona, Spain. | $22.8M / Post-IPO Debt / Jul 27, 2026 | ||
| Super’s Diana develops, manufactures, and markets medicines and supplements for swine, cattle, and poultry livestock in over 30 countries. | May 07, 2026 | ||
| D-Sight is an early treatment for the leading cause of preventable blindness in the working-age population. | $2.4M / Seed / Feb 23, 2026 | ||
| LABIANA GROUP has unique operational flexibility and a great capacity to offer high quality contract manufacturing services to all companies in the sector, regardless of batch size required. | $43.6M / Debt Financing / Feb 19, 2026 | ||
| Phyture Biotech was born as a spin-off company of the Faculty of Pharmacy at the Univerisity of Barcelona (Universitat de Barcelona), created by scientists from the research group Plant Biotechnology: Production of Phytomedicines (2009 SGR 1217). Phyture Biotech builds on the knowledge developed by this research group during more than 30 years,creating commercial products and solutions.Belonging to the Plant Biotechnology sector, Phyture Biotech is specialised in the production of high value active ingredients and recombinant proteins, for its use in the cosmetics and pharmaceutical sectors.Phyture has since renamed to Vytrus Biotech in 2016. | $2.3M / Debt Financing / Jan 14, 2026 | ||
| Rubió is a pharmaceutical company that offers medicines, diagnoses, and nutrition products. | $4.7M / Debt Financing / Jul 16, 2025 | ||
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does ICF - Institut Català de Finances invest in?
ICF - Institut Català de Finances invests primarily in Medical, Health Care and Biotechnology startups, most often at Debt Financing and Seed stage. Most of the 18 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does ICF - Institut Català de Finances invest in?
ICF - Institut Català de Finances typically joins rounds of $2.4M–$10M at Seed and $1.7M–$12M at Debt Financing. These are whole funding-round sizes, not ICF - Institut Català de Finances's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds ICF - Institut Català de Finances took part in.
When did ICF - Institut Català de Finances last invest?
The most recent investment recorded for ICF - Institut Català de Finances closed in Oct 2026. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
